Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia

The most frequent subtype of acute myeloid leukemia (AML) is defined by mutations in the nucleophosmin 1 (NPM1) gene. Mutated NPM1 (ΔNPM1) is an attractive target for immunotherapy, since it is an essential driver gene and 4 bp frameshift insertions occur in the same hotspot in 30%–35% of AMLs, resu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Autores principales: van der Lee, Dyantha I., Reijmers, Rogier M., Honders, Maria W., Hagedoorn, Renate S., de Jong, Rob C.M., Kester, Michel G.D., van der Steen, Dirk M., de Ru, Arnoud H., Kweekel, Christiaan, Bijen, Helena M., Jedema, Inge, Veelken, Hendrik, van Veelen, Peter A., Heemskerk, Mirjam H.M., Falkenburg, J.H. Frederik, Griffioen, Marieke
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2019
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355238/
https://ncbi.nlm.nih.gov/pubmed/30640174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI97482
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares